ArticleIn silico pharmacology2023
Evaluation of piperine analogs against prostate cancer targeting AKT1 kinase domain through network pharmacological analysis.
Article in In silico pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Construction and verification of a prognostic model for prostate cancer based on ribosome biogenesis-related genes.BMC medical genomics · 2025Article
- Review
- Unlocking the full potential of piperine-loaded nanocarriers for cancer treatment.Therapeutic delivery · 2025Review
- Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most fatal malignancy in men after lung cancer, and the fifth leading cause of death. Piperine has been utilized for its therapeutic effects since the time of Ayurveda. According to traditional Chinese medicine, piperine has a wide variety of pharmacological effects, including anti-inflammatory, anti-cancer, and immune-regulating properties. Based on the previous study, Akt1 (protein kinase B) is one of the targets of piperine, it belongs to the group of oncogenes and the mechanism of the Akt1 is an interesting approach for anticancer drug design. From the peer-reviewed literature, five piperine analogs were identified altogether, and a combinatorial collection was formed. However, may not be entirely clear how piperine analogs work to prevent prostate cancer. In the present study, serine-threonine kinase domain Akt1 receptor was employed to analyze the efficacy of piperine analogs against standards using in silico methodologies. Additionally, their drug-likeness was evaluated utilizing online servers like Molinspiration and preADMET. Using AutoDock Vina, the interactions of five piperine analogs and two standards with Akt1 receptor was investigated. Our study reveals that piperine analog-2 (pip2) shows highest binding affinity ( Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.